• SIS3 and Smad3: Research Context and Evidence

  2026-10-08

  SIS3 is described by APExBIO as a selective Smad3 inhibitor, but the supplied peer-reviewed study primarily establishes the relevance of the TGF-β/SMAD3 axis in early-stage lung adenocarcinoma rather than validating SIS3 itself. This overview compares the supplier’s claims with published mechanistic findings, outlines conceptual research applications, and explains evidence limitations across cancer and fibrosis research.

• Etomoxir in Immunometabolism Research

  2026-10-08

  Etomoxir is a pharmacological probe used to examine mitochondrial fatty acid oxidation and its relationship to immune-cell function. This overview compares supplier-reported mechanism, the standardized whole-blood framework described by Zhao and colleagues, and broader evidence relevant to metabolic disorder research, neuroinflammation, and experimental autoimmune encephalomyelitis. It emphasizes that Etomoxir is not a fully selective readout of fatty acid oxidation because reported DGAT activity and model-specific biology can complicate interpretation. The supplied evidence supports conceptual use in immunometabolism studies but does not establish clinical efficacy or prove that whole-blood findings are Etomoxir-specific.

• SB 431542 in Lacrimal Gland Repair Research

  2026-10-07

  A 2024 study reported that a two-small-molecule combination containing SB 431542 supported long-term expansion, later differentiation, and secretory maturation of mouse lacrimal gland epithelial cells. The findings connect selective TGF-β pathway modulation with a potential cell-based strategy for lacrimal gland injury repair, while remaining limited to preclinical evidence.

• TBXA2R–ERM Signaling in TNBC Metastasis

  2026-10-07

  Leguay and colleagues identify TBXA2R as a GPCR that activates ERM proteins through Gαq/11-, Gα12/13-, Rho GTPase-, SLK-, and LOK-associated signaling, connecting receptor activity with triple-negative breast cancer motility and invasion. The findings establish a mechanistic framework for GPCR-driven cytoskeletal remodeling and metastatic colonization, while remaining preclinical and model-dependent.

• Triacetin: Mechanism, Evidence, and Translation

  2026-10-06

  Triacetin, or glyceryl triacetate, sits at the intersection of metabolic signaling, epigenetic biology, oncology, and formulation science. This evidence-led perspective separates reported findings from translational hypotheses and outlines how researchers can evaluate its potential without overstating preclinical evidence.

• BAF53a in Glioma: Invasion, EMT and Prognosis

  2026-10-06

  Meng et al. linked elevated BAF53a expression with poorer overall and progression-free survival in glioma and combined patient-tissue analysis with functional studies in U87 cells. The findings support BAF53a as a candidate prognostic biomarker and provide a mechanistic framework connecting this BAF-complex subunit with proliferation, invasion, and EMT-associated marker changes, while remaining preliminary rather than clinically validated.

• FOXO3–YAP Metabolic Targeting in HCC

  2026-10-05

  A 2026 Oncogene study identifies FOXO3 as a suppressor of coordinated glycolysis and glutaminolysis in hepatocellular carcinoma through direct repression of YAP. Its cell, animal, and patient-derived organoid findings support the FOXO3/YAP axis as a metabolic intervention point, while also leaving important questions about pharmacological specificity and clinical transferability.

• Verteporfin and Senescence: A Careful Evidence Map

  2026-10-05

  Verteporfin, also known as CL 318952, is best understood through an evidence map that separates photodynamic cytotoxicity, autophagy modulation, and true senolytic selectivity. This article connects its reported biology with machine-learning-enabled senolytic discovery while clarifying what the evidence does—and does not—support.

• Verteporfin (CL 318952): Mechanism and Evidence

  2026-10-04

  Verteporfin, also known as CL 318952, is a photosensitizer used in photodynamic therapy for selected ocular neovascularization. Evidence also supports a separate, light-independent interaction with p62, but preclinical cell findings should not be treated as universal potency thresholds or clinical efficacy.

• iRhom2 in Olfaction: Receptor Regulation and Adaptation

  2026-10-03

  Azzopardi and colleagues identify iRhom2 as a distinctive regulator in mouse olfactory sensory neurons and link its expression to odor-dependent transcriptional adaptation. The study connects iRhom2/ADAM17 signaling with olfactory receptor regulation while highlighting important limits on translating results from knockout mice and heterologous cell systems to native olfactory tissue.

• CD38 CAR Binder Structures and Affinity Tuning

  2026-10-02

  Cheng et al. define how the CD38-targeting binders RP02 and 028 engage different antigen surfaces, linking epitope geometry to enzymatic inhibition and CAR-T behavior. The study further shows that the affinity-attenuated 028R103G variant can reduce CAR-T fratricide while retaining cytotoxicity against CD38-positive tumor cells, providing a structure-guided framework for optimizing binder performance.

• A 83-01: Selective ALK-5 Inhibitor Guide

  2026-10-01

  A 83-01 is a selective ALK-5 inhibitor that suppresses TGF-β/Smad signaling and supports epithelial-mesenchymal transition (EMT) research. Product-reported activity includes an approximately 12 nM IC50 and 68% inhibition of ALK-5-induced reporter activity at 1 μM in Mv1LuR4-2 cells.

• Imipramine: A Smarter Autophagy Assay Strategy

  2026-10-01

  Imipramine is a tricyclic antidepressant with applications spanning glioma cell autophagy research, apoptosis assays, and neurobiology. This article develops a decision framework that connects the compound’s research profile with ceramide-driven autophagy findings while clearly separating evidence from testable hypotheses.

• SB 431542 Workflow for ALK5 Inhibition

  2026-09-30

  SB 431542 provides a practical way to test ALK5-dependent TGF-β responses in cancer, immune, and stem/progenitor-cell assays. This workflow combines mechanism-based controls with the long-term myogenic engraftment framework reported in a 2025 human PSC study, while emphasizing dose selection, timing, and interpretation limits.

• N4-Acetylcytidine: RNA Modification Workflows

  2026-09-30

  N4-Acetylcytidine supports controlled studies of free ac4C metabolism, post-transcriptional RNA modification, and enzyme substrate specificity. This guide separates RNA-embedded biology from free acetylated cytidine assays, with practical preparation, controls, troubleshooting, and structure-guided applications.

8607 records 1/574 page Next 12345 下5页 Last page